ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 48 citations in OpenAlex.
- Trial
- A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).Gynecologic oncology · 2018Trial
- Review
- Ovarian cancer targeted therapy: current landscape and future challenges.Frontiers in oncology · 2025Review
- Personalized Versus Precision Nanomedicine for Treatment of Ovarian Cancer.Small (Weinheim an der Bergstrasse, Germany) · 2024Article
- Combined Metronomic Chemo-immunotherapy (CMCI) in Head and Neck Cancers-An Experience from a Developing Country.Indian journal of surgical oncology · 2024Article
- Dickkopf-1 is an immune infiltration-related prognostic biomarker of head and neck squamous cell carcinoma.Aging · 2024Article
- Identification and validation of a prognostic model based on immune-related genes in ovarian carcinoma.PeerJ · 2024Article
- Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy.Gynecologic oncology reports · 2023Article
- Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery.Cancers · 2023Review
- Non-invasive plasma testing for CD274 UTR structural variations by next-generation sequencing in cancer.Cell death discovery · 2023Review
- Pan-cancer Landscape of Programmed Death Ligand-1 and Programmed Death Ligand-2 Structural Variations.JCO precision oncology · 2023Article
- Development of an immunohistochemical assay for Siglec-15.Laboratory investigation; a journal of technical methods and pathology · 2022Article
- Targeting immune checkpoints in gynecologic cancer: updates & perspectives for pathologists.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Review
- A multi-ethnic analysis of immune-related gene expression signatures in patients with ovarian clear cell carcinoma.The Journal of pathology · 2021Article
- Pan-cancer landscape ofJournal for immunotherapy of cancer · 2021Article
- Leveraging Genomics, Transcriptomics, and Epigenomics to Understand the Biology and Chemoresistance of Ovarian Cancer.Cancers · 2021Review
- Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma.Cancers · 2021Article
- Effective Disease Control After Combinatorial Treatment with a PD-1 Antibody and an mTOR Inhibitor for Recurrent Ovarian Clear Cell Carcinomas: A Case Report and Literature Review.OncoTargets and therapy · 2021Article
- Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis.Oncoimmunology · 2020Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.